SUBSCRIBE
SUBSCRIBE
News   Business

Theregen Announces Equity Investment From Guidant Corporation To Develop Anginera(TM) Epicardial Patch

February 7, 2006 | 
1 min read
SAN FRANCISCO--(BUSINESS WIRE)--Feb. 7, 2006--Theregen Corporation today announced that it has received an equity investment from Guidant Corporation (NYSE:GDT), a worldwide leader in the treatment of cardiovascular disease.
Alliances
MORE ON THIS TOPIC
World Management Team in office silhouette 3d rendering
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
 · 
6 min read
 · 
Lori Ellis
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Massachusetts-Based Karyopharm, Azurity Cut Workforces
July 14, 2025
 · 
158 min read
 · 
BioSpace Editorial Staff
AbbVie's office in South San Francisco, California
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Feb 19, 2020 Foster City / CA / USA - Gilead corporate headquarters in Silicon Valley; Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs
Infectious disease
Gilead to Provide New HIV Drug to Lower-Income Countries Through Novel Philanthropic Partnership
July 10, 2025
 · 
2 min read
 · 
Tristan Manalac